Terrapeutics developed a groundbreaking platform discovery technology that combines synthetic biology, sequencing tools, and computational biology to discover novel small molecules produced by soil-based bacteria that tackle ‘undruggable’ targets. 

Terrapeutics’ lead discovery program focuses on pan KRAS inhibitors, the next generation of therapeutic solutions for a drug target whose mutations drive 25% of cancers. The company is working on additional programs that will be announced in the near future. The company has R&D operations in California and Israel.